Table 8.

GEE regression analysis for clinical pregnancy.

Independent variable	POSEIDON group 1			POSEIDON group 2			POSEIDON group 3			POSEIDON group 4
	OR	95% CI	p-value	OR	95% CI	p-value	OR	95% CI	p-value	OR	95% CI	p-value
GH supplementation
Non-GH	_	_		_	_		_	_		_	_
GH	19.16	7.87–46.63	<0.001*	7.44	1.65–33.55	0.009*	10.19	2.39–43.52	0.002*	27.63	4.46–171.11	<0.001*
Age	0.91	0.78–1.08	0.285	0.99	0.84–1.15	0.866	1.02	0.82–1.28	0.853	0.92	0.75–1.13	0.422
BMI	0.94	0.84–1.06	0.346	1.02	0.88–1.18	0.800	1.24	1.03–1.50	0.027*	1.07	0.83–1.37	0.598
AMH	1.06	0.85–1.32	0.594	0.92	0.71–1.19	0.521	2.06	0.19–22.37	0.552	0.37	0.04–3.79	0.399
FSH	0.86	0.67–1.11	0.254	1.13	0.89–1.43	0.308	0.91	0.70–1.18	0.456	0.66	0.44–0.97	0.034*
AFC	0.89	0.80–0.99	0.027*	1.18	1.04–1.34	0.009*	1.06	0.82–1.37	0.676	0.94	0.70–1.27	0.700
COH protocol
GnRH antagonist	_	_		_	_		_	_		_	_
GnRH agonist long	1.52	0.62–3.73	0.359	0.61	0.18–2.02	0.418	1.30	0.27–6.29	0.748	1.80	0.31–10.38	0.508
GnRH agonist ultra-long	1.53	0.44–5.31	0.506	0.43	0.08–2.40	0.338	0.51	0.08–3.22	0.470	0.36	0.05–2.66	0.318
GnRH agonist short	1.51	0.49–4.70	0.472	0.77	0.18–3.36	0.732	0.82	0.14–4.95	0.832	1.50	0.30–7.44	0.621
Duration of Gn	1.25	0.98–1.58	0.071	0.95	0.66–1.37	0.788	0.90	0.59–1.38	0.629	1.63	1.03–2.57	0.036*
Gn dose (per 100 IU)	0.98	0.92–1.04	0.522	1.01	0.93–1.09	0.863	1.06	0.99–1.15	0.112	1.00	1.00–1.00	0.491

GH, growth hormone; BMI, body mass index; AMH, anti-Müllerian hormone; FSH, follicle-stimulating hormone; AFC, antral follicle count; COH, controlled ovarian hyperstimulation; GnRH, gonadotropin-releasing hormone; Gn, gonadotropin.

In bold: The values associated with GH.

*indicates statistical significances of p < 0.05.